New triple therapy targets hard-to-treat liver metastases in colorectal cancer
NCT ID NCT07353268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of an antibody drug (QL1706), a targeted therapy (fruquintinib), and short-course radiotherapy against standard third-line therapy in 76 adults with colorectal cancer that has spread to the liver and cannot be removed by surgery. The goal is to see if the new combo is safer and more effective at delaying cancer growth. Participants must have a specific tumor type (pMMR/MSS) and liver metastases at least 5 cm in size.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?